SCHEMBL16993162

SCHEMBL16993162

CCNc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)c(=O)n(CCCN3CCN(C(=O)OC(C)(C)C)CC3)c2n1

nearest known ligand 0.79

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 20/20 0.79
FGFR2 P21802 20/20 0.79
CSF1R P07333 1/20 0.68
LYN P07948 1/20 0.68
FGFR4 P22455 1/20 0.68
FGFR3 P22607 1/20 0.68
FLT4 P35916 1/20 0.68
KDR P35968 1/20 0.68
BLK P51451 1/20 0.68
BMX P51813 1/20 0.68
JAK3 P52333 1/20 0.68
EIF2AK3 Q9NZJ5 1/20 0.68
TAOK2 Q9UL54 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16993420 0.93 FGFR1 (0.78) FGFR1FGFR2CSF1RLYNFGFR4
SCHEMBL16993313 0.92 FGFR1 (0.80) FGFR1FGFR2CSF1RLYNFGFR4
SCHEMBL16993335 0.91 FGFR1 (0.79) FGFR1FGFR2CSF1RLYNFGFR4
SCHEMBL16993297 0.91 FGFR1 (0.79) FGFR1FGFR2CSF1RLYNFGFR4
SCHEMBL16993036 0.88 FGFR1 (1.00) FGFR1FGFR2CSF1RLYNFGFR4
SCHEMBL17910120 0.88 FGFR1 (0.62) FGFR1FGFR2CSF1RLYNFGFR4
SCHEMBL16993212 0.88 FGFR1 (0.78) FGFR1FGFR2CSF1RLYNFGFR4
SCHEMBL16993041 0.88 FGFR1 (0.78) FGFR1FGFR2CSF1RLYNFGFR4
SCHEMBL16993081 0.87 FGFR1 (0.62) FGFR1FGFR2CSF1RLYNFGFR4
SCHEMBL16993298 0.86 FGFR1 (0.80) FGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3102577-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS Principia Biopharma Inc. (US) 2016-12-14 EP disclosed
WO-2015120049-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA, INC. (US) 2015-08-13 WO disclosed